Galectin Therapeutics Inc GALT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GALT is a good fit for your portfolio.
News
-
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
-
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
-
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
Trading Information
- Previous Close Price
- $3.38
- Day Range
- $3.25–3.41
- 52-Week Range
- $1.29–4.20
- Bid/Ask
- $3.33 / $3.37
- Market Cap
- $208.62 Mil
- Volume/Avg
- 142,639 / 147,721
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
Comparables
Valuation
|
Metric
|
GALT
|
CELC
|
VRDN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 2.99 | 3.48 |
Price/Sales | — | — | 2,160.78 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GALT
|
CELC
|
VRDN
|
|---|---|---|---|
Quick Ratio | 1.64 | 12.78 | 17.93 |
Current Ratio | 1.77 | 13.43 | 18.26 |
Interest Coverage | −13.79 | −12.43 | −137.76 |
Quick Ratio
GALT
CELC
VRDN
Profitability
|
Metric
|
GALT
|
CELC
|
VRDN
|
|---|---|---|---|
Return on Assets (Normalized) | −171.38% | −35.57% | −42.76% |
Return on Equity (Normalized) | — | −49.08% | −82.42% |
Return on Invested Capital (Normalized) | −387.31% | −39.21% | −50.70% |
Return on Assets
GALT
CELC
VRDN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bkhkbwksc | Hqgb | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lgxvmvr | Cxtsfb | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gxfqklc | Bvryjfv | $98.1 Bil | |
MRNA
| Moderna Inc | Cplntkdb | Myr | $39.1 Bil | |
ARGX
| argenx SE ADR | Xfthstqr | Ccj | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Wqfjknkp | Wldj | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fbnkpkcpl | Wyssn | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rpwszcsjz | Mtwnpg | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gndjnxgpm | Lqqdysl | $12.5 Bil | |
INCY
| Incyte Corp | Frdwjssrh | Dlphzy | $11.9 Bil |